How I am using currently approved anti-BCMA agents as a part of the treatment plan for patients with R/R MM.
Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents.
Download this slideset based on the content from a live stream CCO webinar from Sagar Lonial, MD, on optimal use of anti-BMCA antibody–drug conjugates for patients with relapsed/refractory multiple myeloma.
Download this slideset based on the content from a live stream CCO webinar from Thomas G. Martin, MD, on how to integrate CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Download this slideset based on the content from a live stream CCO webinar from Suzanne Lentzsch, MD, PhD, on the latest data on BCMA x CD3 bispecific molecules for patients with relapsed/refractory multiple myeloma.
Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal use of anti-BMCA therapy for patients with relapsed/refractory multiple myeloma.
On-demand webcast of a CCO live webinar on the use of BCMA-targeted agents in relapsed/refractory multiple myeloma.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.